Yu-Hsiang Hsieh1, Jason S Haukoos2, Richard E Rothman3. 1. Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21209, USA. Electronic address: yhsieh1@jhmi.edu. 2. Department of Emergency Medicine, Denver Health Medical Center, Denver, CO, USA; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA; Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA. 3. Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21209, USA; Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD 21209, USA.
Abstract
OBJECTIVE: We sought to evaluate the performance of an abbreviated version of the Denver HIV Risk Score in 2 urban emergency departments (ED) with known high undiagnosed HIV prevalence. METHODS: We performed a secondary analysis of data collected prospectively between November 2005 and December 2009 as part of an ED-based nontargeted rapid HIV testing program from 2 sites. Demographics; HIV testing history; injection drug use; and select high-risk sexual behaviors, including men who have sex with men, were collected by standardized interview. Information regarding receptive anal intercourse and vaginal intercourse was either not collected or collected inconsistently and was thus omitted from the model to create its abbreviated version. RESULTS: The study cohort included 15184 patients with 114 (0.75%) newly diagnosed with HIV infection. HIV prevalence was 0.41% (95% confidence interval [CI], 0.21%-0.71%) for those with a score less than 20, 0.29% (95% CI, 0.14%-0.52%) for those with a score of 20 to 29, 0.65% (95% CI, 0.48%-0.87%) for those with a score of 30 to 39, 2.38% (95% CI, 1.68%-3.28%) for those with a score of 40 to 49, and 4.57% (95% CI, 2.09%-8.67%) for those with a score of 50 or higher. External validation resulted in good discrimination (area under the receiver operating characteristic curve, 0.75; 95% CI, 0.71-0.79). The calibration regression slope was 0.92 and its R(2) was 0.78. CONCLUSIONS: An abbreviated version of the Denver HIV Risk Score had comparable performance to that reported previously, offering a promising alternative strategy for HIV screening in the ED where limited sexual risk behavior information may be obtainable.
OBJECTIVE: We sought to evaluate the performance of an abbreviated version of the Denver HIV Risk Score in 2 urban emergency departments (ED) with known high undiagnosed HIV prevalence. METHODS: We performed a secondary analysis of data collected prospectively between November 2005 and December 2009 as part of an ED-based nontargeted rapid HIV testing program from 2 sites. Demographics; HIV testing history; injection drug use; and select high-risk sexual behaviors, including men who have sex with men, were collected by standardized interview. Information regarding receptive anal intercourse and vaginal intercourse was either not collected or collected inconsistently and was thus omitted from the model to create its abbreviated version. RESULTS: The study cohort included 15184 patients with 114 (0.75%) newly diagnosed with HIV infection. HIV prevalence was 0.41% (95% confidence interval [CI], 0.21%-0.71%) for those with a score less than 20, 0.29% (95% CI, 0.14%-0.52%) for those with a score of 20 to 29, 0.65% (95% CI, 0.48%-0.87%) for those with a score of 30 to 39, 2.38% (95% CI, 1.68%-3.28%) for those with a score of 40 to 49, and 4.57% (95% CI, 2.09%-8.67%) for those with a score of 50 or higher. External validation resulted in good discrimination (area under the receiver operating characteristic curve, 0.75; 95% CI, 0.71-0.79). The calibration regression slope was 0.92 and its R(2) was 0.78. CONCLUSIONS: An abbreviated version of the Denver HIV Risk Score had comparable performance to that reported previously, offering a promising alternative strategy for HIV screening in the ED where limited sexual risk behavior information may be obtainable.
Authors: D Vlahov; D C Des Jarlais; E Goosby; P C Hollinger; P G Lurie; M D Shriver; S A Strathdee Journal: Am J Epidemiol Date: 2001-12-15 Impact factor: 4.897
Authors: D Vlahov; B Junge; R Brookmeyer; S Cohn; E Riley; H Armenian; P Beilenson Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1997-12-15
Authors: Bernard M Branson; H Hunter Handsfield; Margaret A Lampe; Robert S Janssen; Allan W Taylor; Sheryl B Lyss; Jill E Clark Journal: MMWR Recomm Rep Date: 2006-09-22
Authors: Jason S Haukoos; Emily Hopkins; Richard L Byyny; Amy A Conroy; Morgan Silverman; Sheri Eisert; Mark Thrun; Michael Wilson; Brian Boyett; James D Heffelfinger Journal: Acad Emerg Med Date: 2009-08 Impact factor: 3.451
Authors: Rebecca V Liddicoat; Nicholas J Horton; Renata Urban; Elizabeth Maier; Demian Christiansen; Jeffrey H Samet Journal: J Gen Intern Med Date: 2004-04 Impact factor: 5.128
Authors: Martin Hoenigl; Nadir Weibel; Sanjay R Mehta; Christy M Anderson; Jeffrey Jenks; Nella Green; Sara Gianella; Davey M Smith; Susan J Little Journal: Clin Infect Dis Date: 2015-04-22 Impact factor: 9.079
Authors: Justin A Yax; Joshua D Niforatos; Daniel L Summers; Margaret H Bigach; Christine Schmotzer; Barbara M Gripshover; Ann Avery Journal: Public Health Rep Date: 2020-11-09 Impact factor: 2.792